53% mean exon skipping and
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
On 6ix: 6ix.com/news/wave-life-sciences-provides-positive-update-on-proof-of-concept-study-for-wve-n531-in
Watch Wave Life Sciences' latest callWave Life Sciences (NASDAQ:WVE) Q2 2026 Earnings Call · Replay · Jul 30Read the transcript of Wave Life Sciences (NASDAQ:WVE) Q2 2026 Earnings CallWave Life Sciences' next earnings callWave Life Sciences (NASDAQ:WVE) Q3 2026 Earnings Call · Oct 27, 2026 at 8:30 AM EDTRegister
Wave Life Sciences Ltd. on 6ix
Story so far
Earlier from Wave Life Sciences
- Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
- Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
- Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
- Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
- Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
Later from Wave Life Sciences
- Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
- Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
- Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
- Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
Follow Wave Life Sciences into a list and get an email when it puts out news.
Follow Wave Life Sciences